List/Grid

Oncology Subscribe to Oncology

Long-term results encouraging for combination immunotherapy for advanced melanoma

Long-term results encouraging for combination immunotherapy for advanced melanoma

The first long-term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results — long-lasting with high survival rates — researchers report. First author Mario Sznol, M.D., professor of medical oncology at Yale Cancer Center, is presenting the updated data at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago. Sznol, clinical research leader of the melanoma research program at Yale Cancer Center, was the senior author on the original study of combination immunotherapy that was first published in the New England Journal of Medicine and presented at ASCO in 2013 Continue reading

Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease

Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease

A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene, and subsequently was granted regular approval in 2013 Continue reading

One step closer to a breath test for lung cancer

One step closer to a breath test for lung cancer

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present. Continue reading

One step closer to a breath test for lung cancer

One step closer to a breath test for lung cancer

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present. Continue reading

Patients with metastatic colon cancer respond to new combination therapy

Patients with metastatic colon cancer respond to new combination therapy

In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. Continue reading

Patients with metastatic colon cancer respond to new combination therapy

Patients with metastatic colon cancer respond to new combination therapy

In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. Continue reading

Immune therapy for advanced bladder cancer yields promising results

Immune therapy for advanced bladder cancer yields promising results

A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Continue reading

Preventing early menopause in breast cancer patients with new drug treatment

Preventing early menopause in breast cancer patients with new drug treatment

Among young women treated for breast cancer, one of the most distressing side effects of chemotherapy is early menopause. But a major clinical trial has found that the risk of early menopause can be significantly reduced by adding a drug called goserelin to the chemotherapy regimen Continue reading

Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial

Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial

Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs. All of the 31 patients included in the study received a combination of gemcitabine and cisplatin, two drugs normally administered for 12 weeks before surgery to remove the tumors Continue reading

Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial

Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial

Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs. All of the 31 patients included in the study received a combination of gemcitabine and cisplatin, two drugs normally administered for 12 weeks before surgery to remove the tumors Continue reading